#clinical trial

Collection of clinical trial news, found 332 news.

Virobay and LEO Pharma Initiate a Phase 1 Trial of VBY-891, a Compound Intended for Oral Treatment of Psoriasis

-     Virobay, Inc. and LEO Pharma A/S today announced that their collaboration on the development ...

Takeda Submits Marketing Authorisation Application for Vedolizumab in Moderately to Severely Active Ulcerative Colitis

-     Takeda Pharmaceutical Company Limited ("Takeda") today announced that a Marketing ...

UMCG Enrolls First Patients in PneumRx RENEW Pivotal Trial for Treatment of Severe Emphysema

- PneumRx, Inc., a leader in interventional pulmonology, announced today that University Medical Center Groningen has ...

Lilly Releases Update on Corporate Responsibility Efforts

- Eli Lilly and Company (NYSE: LLY) has released its 2011/2012 Corporate Responsibility Update ...

Telome Health Plans Launch of TeloTest(TM), a Novel Wellness Biomarker Based on Telomere Length

- Telome Health, Inc. (THI), developer of the TeloTest(TM) diagnostic test that measures average telomere length, ...

AstraZeneca Begins a New Global Study of FASLODEX® (Fulvestrant) 500 mg Injection

-     FALCON (Fulvestrant and AnastrozoLe COmpared in hormonal therapy Naïve advanced breast ...

FDA Approves New Non-Invasive, Non-Ionizing Radiation Therapy to Treat Pain from Bone Metastases

-ExAblate(R) MRI-guided Focused Ultrasound is effective in reducing pain from bone metastases in patients who could not ...

Takeda Progressing Well in Asia with New Drug Applications (NDA)

- Takeda Global Research and Development (Asia) Pte Ltd (TGRD Asia), a wholly owned subsidiary of Takeda Pharmaceutical ...

QPS Qualitix Opens China Office

- QPS Holdings, LLC, a leading full-service Clinical Research Organization, today announced the launch of its QPS ...

Resverlogix Completes Enrollment In ASSURE Trial

- Resverlogix Corp. (TSX:RVX) today announced that it has completed enrollment in ASSURE, a Phase 2b clinical trial ...

Resverlogix's BET Protein Inhibitor RVX-208 Meets Primary Endpoint

Resverlogix Corp. (TSX: RVX) today announced that the BET protein inhibitor RVX-208 significantly increased HDL-C ...

Taiwan introduces herbal medicine for cancer-related fatigue

A biotech company introduced a herbal medicine for the treatment of cancer-related fatigue (CRF), touting it as the ...

Berg Pharma launches clinical trial on BPM 31543

- Berg Pharma, a Boston-based pharmaceutical company focused on discovery and development of new treatments in cancer ...

Berg Pharma and the Parkinson's Institute ink R&D Collaboration

-     Berg Pharma, a Boston-based pharmaceutical company and the renowned Parkinson's Institute ...

Berg Pharma presents at ASCO, poised to lead field in cancer metabolism

-     Berg Pharma, a Boston-based pharmaceutical company presented at the 2012 American Society of ...